Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Crossref DOI link: https://doi.org/10.1007/s40267-018-0594-z
Published Online: 2018-12-27
Published Print: 2019-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Scott, Lesley J.
Text and Data Mining valid from 2018-12-27
Article History
First Online: 27 December 2018